Skip to content
Screener
Immunic, Inc. logo

Immunic, Inc.

IMUX

Immunic, Inc. is a late-stage biotechnology company focused on developing oral, small molecule therapies for chronic inflammatory and autoimmune diseases.

Market cap
$108.61M+44.9%

Earnings

Q3 2026 report

November 13, 2026

Next report

Date not yet announced

Competitors

Profile

Immunic, Inc. is a late-stage biotechnology company focused on developing oral, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's primary value proposition lies in its clinical-stage pipeline targeting neurologic and gastrointestinal conditions, specifically multiple sclerosis and celiac disease. Its lead programs utilize unique mechanisms of action, such as DHODH inhibition and Nurr1 activation, to provide neuroprotective and anti-inflammatory benefits.

Competitive position

A late-stage clinical developer with a unique dual-action mechanism (neuroprotection and anti-inflammation) in the competitive multiple sclerosis market.

GeographiesUnited States, Germany, Australia
Customer segmentsPatients, Healthcare Providers
Business modelR&D intensive, Licensing and Royalties
SuppliersContract Research Organizations (CROs), Academic research partners, Specialized chemical manufacturers, Clinical trial sites
CustomersPharmaceutical companies (potential licensees), Specialty pharmacies, Hospitals and clinics
Listed2014
Employees80.0
CEOErik Lundgren
Websiteimux.com
FilingsSEC EDGAR

FAQ

What is Immunic, Inc.'s market cap?
Immunic, Inc. (IMUX) has a market capitalization of $108.6M and trades on NASDAQ.
Who are Immunic, Inc.'s competitors?
Immunic, Inc.'s key competitors include Biogen Inc., Medicinova, Inc., Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
Who does Immunic, Inc. partner with?
Immunic, Inc.'s notable partners include Fraunhofer Institute, Leerink Partners LLC, BVF Partners, L.P., and others.
What subsidiaries does Immunic, Inc. have?
Immunic, Inc.'s subsidiaries include Gliomic Therapeutics Inc., Immunic Australia.
Where is Immunic, Inc. headquartered?
Immunic, Inc. is headquartered in United States of America and employs approximately 80 people. It has been publicly traded since 2014.